Clinical Trials

Urinary Bladder Neoplasms

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

95 enrolled

Urinary Bladder Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

200 enrolled

Prostatic Neoplasms

NCT04336943 2025-08-11

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

6 enrolled 10 charts

Biochemically Recurrent Prostate Carcinoma

NCT02788773 2025-05-15

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

52 enrolled 12 charts

Prostatic Neoplasms

NCT03601455 2025-04-13

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

13 enrolled

Urinary Bladder Neoplasms

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT03702179 2024-12-05

IMMUNOPRESERVE

32 enrolled 19 charts

Invasive Bladder Cancer

NCT02819596 2024-11-04

CALYPSO

69 enrolled

Carcinoma, Renal Cell

NCT03204812 2024-10-15

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

31 enrolled 12 charts

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT06591650 2024-09-19

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

33 enrolled

GastrointestinalGenitourinary

Gallbladder Cancer Unresectable

NCT03795207 2024-08-02

POSTCARD

96 enrolled

Node; Prostate

NCT04089553 2024-04-16

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

59 enrolled 19 charts

Prostatic Neoplasms

NCT03810105 2024-04-09

A Study of Olaparib and Durvalumab in Prostate Cancer

5 enrolled 4 charts

Prostatic Neoplasms

NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

7 enrolled 9 charts

GenitourinarySarcoma

Bladder Adenocarcinoma

NCT04495179 2023-08-09

AARDVARC

30 enrolled 22 charts

Prostatic Neoplasms

NCT03472274 2023-04-13

DUTRENEO

101 enrolled

Urinary Bladder Neoplasms

NCT04543110 2023-03-23

RADIANT

16 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT02901548 2022-07-29

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

17 enrolled 9 charts

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT03759496 2022-03-23

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

39 enrolled

Urinary Bladder Neoplasms, Neoplasms

NCT03430895 2021-12-01

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

15 enrolled 8 charts

Urinary Bladder Neoplasms

NCT04579133 2021-06-16

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

140 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03081923 2021-05-14

APACHE

36 enrolled

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT03824691 2021-02-25

ARCADIA

122 enrolled

Urinary Bladder Neoplasms

NCT04262375 2020-11-17

DOMINATION

Phase 2 Withdrawn

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT03598816 2020-08-13

PIVOT-RCC

Phase 2 Withdrawn

Carcinoma, Renal Cell

NCT03234153 2020-06-17

NITIMIB

6 enrolled

Muscle-invasive Bladder Cancer

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

40 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03534492 2020-04-06

NEODURVARIB

29 enrolled

Urinary Bladder Neoplasms

NCT02669914 2018-11-06

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

4 enrolled 12 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03150836 2017-10-19

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Phase 2 Withdrawn